Comparative Pharmacology
Head-to-head clinical analysis: VABYSMO versus ZALTRAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VABYSMO versus ZALTRAP.
VABYSMO vs ZALTRAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vabysmo (faricimab) is a bispecific monoclonal antibody that binds to vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), inhibiting their activity. By blocking VEGF-A, it reduces endothelial cell proliferation, vascular permeability, and angiogenesis. By inhibiting Ang-2, it stabilizes blood vessels by enhancing pericyte coverage and reducing vascular leakage and inflammation.
Vascular endothelial growth factor (VEGF) trap; binds to VEGF-A, VEGF-B, and PlGF, inhibiting angiogenesis.
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.
4 mg/kg intravenously over 1 hour every 2 weeks
None Documented
None Documented
Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
17-18 days (terminal half-life) with clinical context supporting a dosing interval of every 2 weeks; steady-state achieved by approximately 16 weeks.
Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Primarily via the reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Renal elimination accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor